146 related articles for article (PubMed ID: 34580845)
41. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
42. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
43. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J
Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512
[TBL] [Abstract][Full Text] [Related]
44. PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.
De Bacco MW; Carvalhal GF; MacGregor B; Marçal JMB; Wagner MB; Sonpavde GP; Fay AP
Clin Genitourin Cancer; 2020 Jun; 18(3):e254-e259. PubMed ID: 32139302
[TBL] [Abstract][Full Text] [Related]
45. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
46. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
[TBL] [Abstract][Full Text] [Related]
47. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
48. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.
Qiao PP; Tian KS; Han LT; Ma B; Shen CK; Zhao RY; Zhang Y; Wei WJ; Chen XP
Endocrine; 2022 Jun; 76(3):660-670. PubMed ID: 35366156
[TBL] [Abstract][Full Text] [Related]
49. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Vallonthaiel AG; Malik PS; Singh V; Kumar V; Kumar S; Sharma MC; Mathur S; Arava S; Guleria R; Jain D
Ann Diagn Pathol; 2017 Dec; 31():56-61. PubMed ID: 29146060
[TBL] [Abstract][Full Text] [Related]
51. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
52. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Hu C; Tian S; Lin L; Zhang J; Ding H
Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
[TBL] [Abstract][Full Text] [Related]
53. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
[TBL] [Abstract][Full Text] [Related]
54. Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Farkašová A; Tancoš V; Kviatkovská Z; Huťka Z; Mičák J; Scheerová K; Szépe P; Plank L
Cesk Patol; 2018; 54(3):137-142. PubMed ID: 30445818
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
[TBL] [Abstract][Full Text] [Related]
56. Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
Ağaçkıran Y; Aksu F; Akyürek N; Ercan C; Demiröz M; Aksu K
Asia Pac J Clin Oncol; 2021 Jun; 17(3):280-288. PubMed ID: 32929886
[TBL] [Abstract][Full Text] [Related]
57. The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma.
Al-Jussani GN; Alsughayer A; Yousuf MS; Mullahuwash Y; Dabbagh T; Sughayer MA
Int J Biol Markers; 2022 Sep; 37(3):322-327. PubMed ID: 35635229
[TBL] [Abstract][Full Text] [Related]
58. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
59. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
[TBL] [Abstract][Full Text] [Related]
60. Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition.
Kwon MJ; Rho YS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Kim ES; Park B; Hong M; Min KW
Hum Pathol; 2018 Oct; 80():28-39. PubMed ID: 29634978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
